Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
Completed · Phase 1
Conditions studied: Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
In brief
The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.
Key facts
- Study ID
- NCT02808312
- Run by
- Gilead Sciences
- People needed
- 57
- Starts
- 2016-07-13
- Expected to finish
- 2018-10-16
- Last updated by the study team
- 2021-01-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Miami, Florida, United States
- Study site — Orlando, Florida, United States
- Study site — Knoxville, Tennessee, United States
- Study site — San Antonio, Texas, United States
- Study site — Auckland, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.